Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
40 participants
INTERVENTIONAL
2020-04-29
2022-07-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CPX-351 Therapy for MDS After Hypomethylating Agent Failure
NCT03957876
Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm
NCT04992949
CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS
NCT04668885
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
NCT03896269
CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics
NCT05260528
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
CPX-351 is an advanced liposomal formulation of daunorubicin and cytarabine encapsulated at a 1:5 ratio.
Patients will receive induction treatment with CPX-351. Patients in response (complete response (CR), complete response with incomplete hematologic improvement (CRi), partial response (PR)) after induction will receive monthly courses of consolidation therapy with CPX-351.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort A - First line treatment
Untreated patients
CPX-351 in cohort A
Treatment by CPX-351 via intravenous infusion over 90 minutes.
Induction treatment with CPX-351 100 Units/m²/D on days 1, 3 and 5.
If response after this induction treatment, 4 courses of consolidation therapy with CPX-351 100 Units/m²/D on day 1.
If no response after this induction treatment, a second induction course of CPX-351 100 Units/m²/D on days 1 and 3. If response is achieved after this salvage course, 3 courses of consolidation therapy with CPX-351 100 Units/m²/D on day1.
Cohort B - Hypomethylating failure
Patients in absence of response after hypomethylating agents treatment
CPX-351 in cohort B
Treatment by CPX-351 via intravenous infusion over 90 minutes.
This will be a dose-finding study : CPX-351 100 Units/m²/D on days 1, 3 and 5 or CPX-351 100 Units/m²/D on days 1 and 3 or CPX-351 60 Units/m²/D on days 1 and 3.
In response after induction treatment, 4 monthly courses of consolidation therapy with CPX-351 at the same dose on day 1.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CPX-351 in cohort A
Treatment by CPX-351 via intravenous infusion over 90 minutes.
Induction treatment with CPX-351 100 Units/m²/D on days 1, 3 and 5.
If response after this induction treatment, 4 courses of consolidation therapy with CPX-351 100 Units/m²/D on day 1.
If no response after this induction treatment, a second induction course of CPX-351 100 Units/m²/D on days 1 and 3. If response is achieved after this salvage course, 3 courses of consolidation therapy with CPX-351 100 Units/m²/D on day1.
CPX-351 in cohort B
Treatment by CPX-351 via intravenous infusion over 90 minutes.
This will be a dose-finding study : CPX-351 100 Units/m²/D on days 1, 3 and 5 or CPX-351 100 Units/m²/D on days 1 and 3 or CPX-351 60 Units/m²/D on days 1 and 3.
In response after induction treatment, 4 monthly courses of consolidation therapy with CPX-351 at the same dose on day 1.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* For COHORT A: untreated patients except by erythropoiesis stimulating agents, Lenalidomide or non-chemotherapy during a phase of lower risk MDS; For COHORT B: absence of response (CR, CRi, PR or HI according to international working group (IWG) 2006 for MDS) after a minimum of 6 cycles of single hypomethylating agent or relapse after a response.
* For COHORT A: less than 20% of marrow blasts. For COHORT B: less than doubling of marrow blasts compared with onset of hypomethylating agent.
* Classical international prognostic scoring system (IPSS) int-2 or high risk score.
* For COHORT A and B : age between 18 and 70 years
* For COHORT A: Performance status (ECOG grading) ≤ 1; For COHORT B: Performance status ≤ 2.
* Eligible for standard intensive chemotherapy.
* Absence of concomitant severe cardiovascular disease which would make intensive chemotherapy impossible, i.e. arrhythmias requiring chronic treatment, congestive heart failure or symptomatic ischemic heart disease, reduced left ventricular function assessed by multigated acquisition (MUGA) scan or echocardiogram.
* Patient must have adequate organ function as indicated by the following laboratory values: Renal: Serum creatinine \< 2 mg/dl or calculated creatinine clearance ≥ 60 mL/min by MDRD (modification of the diet in renal disease) or CKD-EPI (chronic kidney disease epidemiology collaboration) equation for patients with creatinine levels \> 1.5xULN ; Hepatic: Serum total bilirubin ≤ 2.5xULN OR direct bilirubin ≤ ULN for patients with total bilirubin levels ≥ 2 mg/dL, aspartate aminotransferase (ALT) and alanine aminotransferase (ALT) ≤ 2.5xULN, Alkaline Phosphatase ≤ 5xULN (if \> 2.5xULN, then liver fraction should be ≤ 2.5xULN).
* Patients not known to be refractory to platelet transfusions.
* Female subjects of child-bearing potential must agree to undergo medically supervised pregnancy test prior to starting study drug. The first pregnancy test will be performed at screening (within 7 days prior to first study drug administration), and on the day of the first study drug administration and confirmed negative prior to dosing and Day 1 before dosing all subsequent cycles. Female patient is not actively breastfeeding at the time of study entry.
* Female patients are either post-menopausal, free from menses for \> 2 years, surgically sterilized or willing to use 2 adequate barrier methods of contraception to prevent pregnancy or agree to abstain from becoming pregnant throughout the study, starting with Visit 1. Females of reproductive potential as well as fertile men and their partners who are female of reproductive potential must agree to abstain from sexual intercourse or to use two highly effective forms of contraception from the time of giving informed consent, during the study and for 6 months (females and males) following the last dose of CPX-351.
* Male patients agree to use an adequate method of contraception for the duration of the study. Men should be advised not to father a child while receiving CPX-351 and for 6 months post study.
* Patients are available for regular blood sampling, study related assessments, and appropriate clinical management at the treating institution for the duration of the study.
* Patients have the ability to understand and willingness to sign an informed consent form indicating the investigational nature of the study.
Exclusion Criteria
* Last dose of hypomethylating agent given more than 4 months before entering the trial.
* Uncontrolled intercurrent illness or circumstances that could limit compliance with the study, including but not limited to the following: symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, pancreatitis, or psychiatric or social conditions that may interfere with patient compliance.
* Current participation or participation in a study with an investigational compound or device within 30 days of initial dosing with study drug.
* Known human immunodeficiency virus (HIV) infection or HIV-related malignancy.
* Clinically active hepatitis B or hepatitis C infection.
* Known allergy or hypersensitivity to any component of CPX-351.
* "Currently active" second malignancy, other than non-melanoma skin cancer and in situ carcinoma of the cervix.
* Subjects with a history of Wilson's disease or other copper-related disorder.
* Treatment with growth factors such as erythropoietin alfa (EPO) or granulocyte colony-stimulating factor (G-CSF) or cytotoxic and non-cytotoxic agents (including low dose oral chemotherapy with the exception of hydroxyurea) in the 30 days before inclusion.
* Treatment with systemic steroids that has not been stabilized to the equivalent of ≤ 10 mg/day prednisone during the 4 weeks prior to the start of the study drugs.
* Clinical evidence of central nervous system leukemia.
* Pregnancy or breastfeeding during the projected duration of the study.
* Absence of social security.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Groupe Francophone des Myelodysplasies
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pierre PETERLIN, MD
Role: PRINCIPAL_INVESTIGATOR
Nantes University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU d'Amiens - Service d'hématologie clinique et thérapie cellulaire
Amiens, , France
CHU d'Angers - Service des maladies du sang
Angers, , France
Centre hospitalier Victor Dupouy - Service d'Hématologie
Argenteuil, , France
CHU de Besançon - Hôpital Jean Minjoz - Service d'hématologie clinique
Besançon, , France
CHU de Grenoble - Clinique universitaire d'hématologie
Grenoble, , France
CH Le Mans - Service d'onco-hématologie
Le Mans, , France
CHRU de Limoges - Hôpital Dupuytren - Service d'hématologie clinique et thérapie cellulaire
Limoges, , France
Institut Paoli Calmettes - Unité d'hématologie 3
Marseille, , France
CHU Hôtel Dieu - Service d'Hématologie Clinique
Nantes, , France
CHU-Hôpital Archet I - Service d'Hématologie Clinique
Nice, , France
Hôpital Saint Louis - Service Hématologie Séniors
Paris, , France
CHU de Bordeaux - Hôpital de Haut-Lévêque - Service des maladies du sang
Pessac, , France
CHU de Poitiers - Service d'onco-hématologie et thérapie cellulaire
Poitiers, , France
Hôpital Pontchaillou - Service d'hématologie clinique
Rennes, , France
Institut de Cancérologie Lucien Neuwirth - Hématologie Clinique - Thérapie Cellulaire
Saint-Priest-en-Jarez, , France
IUCT-oncopole - Fédération Hématologie - Médecine Interne
Toulouse, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Peterlin P, Le Bris Y, Turlure P, Chevallier P, Menard A, Gourin MP, Dumas PY, Thepot S, Berceanu A, Park S, Hospital MA, Cluzeau T, Bouzy S, Torregrosa-Diaz JM, Drevon L, Sapena R, Chermat F, Ades L, Dimicoli-Salazar S, Chevret S, Bene MC, Fenaux P. CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Haematol. 2023 Jul;10(7):e521-e529. doi: 10.1016/S2352-3026(23)00090-X. Epub 2023 May 25.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GFM-CPX-MDS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.